200 related articles for article (PubMed ID: 7069575)
1. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
2. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Giacomini KM; Blaschke TF
Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
[TBL] [Abstract][Full Text] [Related]
3. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
Cunningham JL; Shen DD; Shudo I; Azarnoff DL
Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
[TBL] [Abstract][Full Text] [Related]
4. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Lima JJ; Haughey DB; Leier CV
J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of disopyramide in normal volunteers using unbound concentration.
Braun J; Sörgel F; Gluth WP; Oie S
Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
[TBL] [Abstract][Full Text] [Related]
6. The influence of protein binding on disopyramide clearance.
Bryson SM; Lawrence JR; Steele WH; Campbell BC; Elliott HL; Sumner DJ
Eur J Clin Pharmacol; 1982; 23(5):453-6. PubMed ID: 7151851
[TBL] [Abstract][Full Text] [Related]
7. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Haughey DB; Lima JJ
Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of disopyramide.
Siddoway LA; Woosley RL
Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
Lima JJ; Boudoulas H; Shields BJ
Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
11. In vivo interaction of the enantiomers of disopyramide in human subjects.
Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
13. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
14. Disopyramide kinetics in renal impairment: determinants of interindividual variability.
Burk M; Peters U
Clin Pharmacol Ther; 1983 Sep; 34(3):331-40. PubMed ID: 6883909
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
16. Immediate- versus controlled-release disopyramide: importance of saturable binding.
Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
[TBL] [Abstract][Full Text] [Related]
17. Effect of altered disopyramide binding on its pharmacologic response in rabbits.
Huang JD; Oie S
J Pharmacol Exp Ther; 1982 Nov; 223(2):469-71. PubMed ID: 7131300
[TBL] [Abstract][Full Text] [Related]
18. Disopyramide concentrations in saliva.
Aitio ML; Virtanen R; Lammintausta R
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide.
Lima JJ; Shields BJ; Howell LH; MacKichan JJ
Ther Drug Monit; 1984; 6(2):203-10. PubMed ID: 6377599
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Johnston A; Henry JA; Warrington SJ; Hamer NA
Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
